Twitxy Saved

David Gandara

@drgandara

Medical Oncologist & clinical-translational researcher in lung cancer. Co-Director-Center for Experimental Therapeutics, UC Davis Comprehensive Cancer Center
Joined December 2016
548 Following 8.1K Followers 6.4K Posts

Latest posts 5

David Gandara @drgandara
Great questions regarding FDA decision making process. For better or worse, at least we should expect FDA to show consistency. The current tsunami of China-only or China-mainly or China-plus submissions is unprecedented, requiring consistency rather than trial by trial decisions.
Dr Amol Akhade Verified account @SuyogCancer 3d
One of the reasons why @FDA rejected Ivonescimab approval claim is that 93 % events occur in China.
I have two questions
1- what is the cut off for events to occur in USA for USFDA to consider that data as good enough? Is there a number? 40 % , 50 % , 60 % ?
2 - Guess this trial and tell me how usfda will react to its results ? It has only 39 pts out of 602 ( 6.4 % ) from USA and in pre specified subset analysis they dont do well ( see the graph on right )
Hint - trial got maximum applause at #esmo26 .
The slide is from our upcoming OncoWisdom webinar on 20 th November to discuss esmo26 key data . @Timothee_MD @StephenVLiu @JacobPlieth @KolPulseAI @NeilVasan @JackWestMD
View quoted post on X
0 replies 3 reposts 20 likes 2.3K views View on X
David Gandara @drgandara
Re-ESMO algorithm for EGFR mutated NSCLC upon PD, pathway seems confusing, at least to me. It states that if a mechanism resistance is defined, then the patient should go onto a clinical trial. Does not specify MET directed therapy if that MOR is identified. Maybe I am misreading
Yakup Ergün Verified account @dr_yakupergun 3d
ESMO has updated selected recommendations for targeted therapies and ADCs in oncogene-addicted metastatic NSCLC

Updated treatment recommendations👇
annalsofoncology.org/article/S0923-…
View quoted post on X